Pittsburgh, Pennsylvania and Toronto, Ontario–(Newsfile Corp. – May 22, 2025) – Sharp Therapeutics Corp. (TSXV: SHRX) (“Sharp” or the “Company”), a pre-clinical-stage biotechnology company developing small molecule therapies to treat genetic diseases, announces the release of its condensed interim consolidated financial statements for the three months ended March 31, 2025, …
Read More »Sharp Therapeutics Corp. Nominates Clinical Candidate for Gaucher’s Disease
Pittsburgh, Pennsylvania and Toronto, Ontario–(Newsfile Corp. – May 13, 2025) – Sharp Therapeutics Corp. (TSXV: SHRX) (“Sharp” or the “Company”), a pre-clinical-stage biotechnology company developing small molecule therapies to treat genetic diseases, announces that it has nominated a small molecule compound from its GBA program for clinical development in Gaucher’s …
Read More »STX PARTNERS LLP and Newlin Investment Co. Exercise Warrants of Sharp Therapeutics Corp.
Pittsburgh, Pennsylvania and Toronto, Ontario–(Newsfile Corp. – April 21, 2025) – Sharp Therapeutics Corp. (TSXV: SHRX) (“Sharp” or the “Company”), a pre-clinical-stage biotechnology company developing small molecule therapies to treat hereditary disorders, is pleased to announce that STX PARTNERS LLP (“STX”) and Newlin Investment Company (“NIC”) have each exercised their …
Read More »
Matribhumi Samachar English